Sexual Health Testing Market - By Device Type (Laboratory Devices, Point of Care (PoC) Devices), By Application (Chlamydia, Gonorrhoea, Syphilis, Genital Herpes, Hepatitis B, HIV/AIDS), By End-use – Global Forecast to 2032

Sexual Health Testing Market Size

Sexual Health Testing Market size was valued at over USD 90 billion in 2022 and is projected to register over 5.3% CAGR between 2023 and 2032 owing to rising awareness regarding STDs and its diagnosis.
 

Sexual health testing refers to the process of diagnosing and screening for sexually transmitted infections (STIs) and other conditions related to sexual health. Testing is crucial for identifying infections, determining appropriate treatment, and preventing the spread of diseases. Additionally, the high prevalence of sexually transmitted diseases (STDs) is accelerating market growth. For instance, STDs have a substantial global impact, affecting millions of people each year. According to the World Health Organization (WHO), there are an estimated 376 million new cases of four common sexually transmitted infections including gonorrhoea, chlamydia, syphilis, and trichomoniasis, annually.
 

Moreover, STD prevalence rate can vary significantly between regions and countries. Factors such as socioeconomic conditions, healthcare infrastructure, education, cultural norms, and sexual behaviours contribute to these variations. Additionally, stigma associated with STDs and sexual health, lack of awareness, and limited access to healthcare services can function as barriers to testing and prevention. Thus, regular microbiology testing, early diagnosis, and timely treatment are crucial for reducing the prevalence of STDs, thereby augmenting STD diagnostics market growth. In addition, several market players are emphasizing on research and development activities for the development of novel sexual health testing.
 

COVID-19 Impact

The COVID-19 epidemic had a moderately negative impact on the sexual health testing market. The pandemic led to disruptions in healthcare systems globally, with resources and attention primarily focused on managing and responding to COVID-19. This resulted in reduced availability and access to routine sexual health services, including testing. Due to the overwhelming demand for COVID-19 testing and vaccination efforts, resources and healthcare personnel were redirected to pandemic-related activities. This diversion of resources affected the overall capacity for sexual health testing.
 

However, post pandemic to adapt to the challenges posed by the pandemic, healthcare providers have increasingly adopted telemedicine and remote testing options. These may include virtual consultations, home testing kits for certain infections, and remote monitoring of sexual health conditions. Such innovations have helped bridge the gap in access to sexual health testing. Therefore, COVID-19 pandemic hindered the STD diagnostics market growth.
 

Sexual Health Testing Market Trends

Increasing government initiatives towards sexually transmitted diseases (STDs) are crucial in addressing the challenges associated with these infections. Governments worldwide have recognized the importance of prevention, awareness, testing, treatment, and support services for individuals affected by STDs. Governments often promote and support vaccination programs for diseases such as human papillomavirus (HPV) and hepatitis B virus (HBV), which can be sexually transmitted. These programs target specific age groups, such as adolescents, to protect individuals before they become sexually active. Thus, such initiatives will lead to high product demand in the near future.
 

Sexual Health Testing Market Analysis

Based on device type, the sexual health testing market is segmented into laboratory devices and point of care (PoC) devices. The laboratory devices segment is further bifurcated into PCR (polymerase chain reaction), flow cytometers, enzyme linked immunosorbent assay (ELISA), and others. The point of care (PoC) devices segment is further subdivided into rapid diagnostic kits and microfluidics & immunochromatographic testing (ICT). The laboratory devices segment held the largest revenue size over USD 60 billion in 2022 and is estimated to witness significant growth more than USD 100 billion by 2032. Laboratory tests often provide higher accuracy and sensitivity compared to POC tests. They are designed to detect and quantify specific markers, such as antibodies or antigens, associated with sexually transmitted infections (STIs).
 

Laboratory tests undergo rigorous validation and quality control measures, ensuring reliable and precise results. Furthermore, an increase in the availability of device type coupled with several other businesses working towards creating innovative technology will support the segment's revenue growth.
 

STD diagnostics market is bifurcated based on the application including chlamydia, gonorrhoea, syphilis, genital herpes, hepatitis B, HIV/AIDS, others. The chlamydia segment dominated the market and is anticipated to grow over USD 36 billion by 2032. Chlamydia is one of the most commonly reported sexually transmitted infections (STIs) worldwide, and its prevalence has been increasing over the years. For instance, according to the World Health Organization (WHO), an estimated 127 million new cases of chlamydia occur, annually.
 

The sexual health testing market is segmented by end-use into hospitals, diagnostic centers, and others. Diagnostic centers segment dominated the global market accounting for more than 52% business share in 2022 and is estimated to witness significant revenue over USD 82 billion by 2032. The diagnostic centers segment is anticipated to hold high growth potential during the analysis period. Factors such as surging laboratory tests and rising preference towards diagnostics laboratories due to presence of advanced technologies and cost-effective treatment will fuel market growth. Additionally, these centers provide early and accurate disease diagnosis and patient management, thus, anticipated to augment the segment trends.
 

U.S. sexual health testing market accounted for more than USD 33 billion in 2022 and will grow momentously more than USD 55 billion by 2032. The affordability of sexual health testing among the target population base and ongoing technological developments are primarily responsible for the growth of the STD diagnostics market in United States. Further, the region's high healthcare spending on health care management and rising disposable income will propel the expansion of the North America market. Also, the substantial presence of well-established market participants and the favourable regulatory environment result in a number of product approvals and launches, particularly in the U.S.
 

Sexual Health Testing Market Share

Some of the notable key industry players operating in the sexual health testing market include

• bioMérieux SA
• Hologic, Inc.
• OraSure Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Abbott Laboratories
• Merck & Co. Inc.
• Johnson & Johnson Services, Inc
• GlaxoSmithKline Plc.
• Allergen
• Bayer AG
• Bristol-Myers Squibb Company
• Bausch Health Companies Inc.
• Boehringer Ingelheim International GmbH
• Sorrento Therapeutics, Inc.
• WEX Pharmaceuticals Inc.
• Zynerba Pharmaceuticals, Inc.
• Medtronic Inc.
• Boston Scientific Corporation
• Halyard Health, Inc.
• Neurotech Na, Inc.
   

Sexual Health Testing Industry News:

• In February 2023, BD received U.S. FDA approval for its product called Onclarity HPV Assay that is used along with ThinPrep PAP test. The test detects HPV types 16,18, 45 along with genotypes 31, 51, 52, 33/58, 35/39/68, and 56/59/66. Such advanced product launches are anticipated to bolster STD diagnostics market statistics.
   

Sexual health testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Device Type (USD Million)

• Laboratory devices   
• PCR (Polymerase Chain Reaction)
• Flow cytometers
• Enzyme linked immunosorbent assay (ELISA)
• Others

• Point of care (PoC) devices 
• Microfluidics and immunochromatographic testing (ICT)
• Rapid diagnostic kits

By Application (USD Million)

• Chlamydia
• Gonorrhoea
• Syphilis
• Genital herpes
• Hepatitis B
• HIV/AIDS (Human immunodeficiency virus infection and acquired immune deficiency syndrome)

By End-use (USD Million)

• Hospitals
• Diagnostic centers
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Russia
  • Poland
  • Switzerland
  • Norway
  • Finland
  • Sweden
  • Denmark
  • The Netherlands
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Taiwan
  • Indonesia
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE